T2 Biosystems

Species ID direct from whole blood The standard of care for sepsis includes reliance on empiric therapy and blood culture tests, delaying clinical decisions while patient conditions may continue to worsen. It’s estimated that about 20% of patients with septic shock receive inappropriate initial antimicrobial therapy, which is associated with a fivefold reduction in survival.1 The T2Bacteria, T2Candida, and T2Resistance Panels provide identification of the most prevalent bacterial and fungal pathogens and genetic markers of resistance within 3 to 5 hours of the first patient blood draw and are independent of blood culture. Results from the panels provide clinicians with critical data needed to influence treatment decisions sooner, often before the second dose of broad-spectrum antimicrobials is administered.